Novel research strategies in the pharmacology of schizophrenia

Drugs of Today

Volumn 33, Issue 2, 1997, Pages 103-113

  Lipska, Barbara K ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR;

ANIMAL MODEL; ARTICLE; DRUG RESEARCH; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; SCHIZOPHRENIA;

EID: 0030911151     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Hyde, T., Casanova, M., Kleinman, J.E., Weinberger, D.R. Neuroanatomical and neurochemical pathology in schizophrenia. In: American Psychiatric Press Review of Psychiatry, Vol. 10. Tasman. A. (Ed.). APPA Press: Washington, DC 1991, 275-81.
2. Laruelle, M., Abi-Dargham, A., Van Dyck, C.H. et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996, 93: 9235-40.
3. Carpenter, W.T., Conley, R.R., Buchanan, R.W., Breier, A., Tamminga, C. Patient response and resource management: Another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995, 152: 827-32.
4. Jackson, D.M., Ryan, C., Evenden, J., Mohell, N. Preclinical findings with new antipsychotic agents: What makes them atypical? Acta Psychiatr Scand Suppl 1994, 380: 41-8.
5. Creese, I., Burt, D.R., Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192: 481-3.
6. Seeman, P., Lee, T., Chau-Wong, M., Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261: 717-9.
7. i values. J Pharmacol Exp Ther 1989, 251: 238-46.
8. Meltzer, H.Y. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989, 99: S18-27.
9. 2 dopamine receptor. Proc Natl Acad Sci USA 1989, 86: 9762-6.
10. 3) as a target for neuroleptics. Nature 1990, 347: 146-51.
11. 1 receptor encoded by an intronless gene on chromosome 5. Nature 1990, 347: 80-3.
12. 1. Nature 1991, 350: 614-9.
13. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991, 350: 610-4.
14. 3 receptor gene: Organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet (Neuropsychiatric Genet) 1996, 67: 63-70.
15. 3 receptor MRNA expression in the parietal and motor cortex in patients with chronic schizophrenia. Proc Natl Acad Sci USA 1993, 90: 8942-6.
16. 3-receptor pre-mRNA in chronic schizophrenia. J Neurosci 1996, 16: 7902-9.
17. 3 receptors and use of antipsychotics in schizophrenic patients: A postmortem study. Arch Gen Psychiatry 1997, in press.
18. 4. Neuropsychopharmacology 1992, 7: 261-84.
19. 4 receptors elevated in schizophrenia. Nature 1993, 365: 441-5.
20. 4 dopamine receptors in postmortetn striatum from patients with schizophrenia. J Neurosci 1995, 15: 2186-91.
21. 4 receptors by 2-fold in rats. Eur J Pharmacol 1995, 289: 67-72.
22. Meador-Woodruff, J.H., Mansour, A., Saul, J., Watson, S.J. Dopamine receptors and transporters: Pharmacology, structure and function. In: Neuroanatomical Distribution of Dopamine Receptor Messenger RNAs. Niznik, H.B. (Ed.). Marcel Dekker: New York 1994, 401-14.
23. 4 receptors. Abstr Soc Neurosci 1996, 22: 1772.
24. 4-selective antagonist U-101387G, blocks amphetamine-sensitization in rats: Behavioral and biochemical changes. Abstr Soc Neurosci 1996, 22: 1773.
25. 4 receptor selective antagonist. J Pharmacol Exp Ther, in press.
26. 4-selective antagonist. Abstr Soc Neurosci 1996, 22: 1773.
27. Inayama, Y., Yoneda, H., Sakai, T. et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet (Neuropsychiatric Genet) 1996, 67: 103-5.
28. Williams, J., Spurlock, G., McGuffin, P. et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicenter Association Study of Schizophrenia (EMASS) Group. Lancet 1996, 347: 1294-6.
29. Sailer, C.F., Salama, A.I. Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993, 112: 285-92.
30. Leysen, J.E., Janssen, P.M., Megens, A.A.H.P., Schotte, A. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994, 55 (Suppl.): 5012.
31. 1C receptors. Abstr Soc Neurosci 1993, 19: 599.
32. Moore, N.A., Calligaro, D.O., Wong, D.T., Bymaster, F., Tye, N.C. The pharmacology of olanzepine and other new antipsychotic agents. Curr Opin Invest Drugs 1993, 2: 281-93.
33. Gerlach, J., Peacock, L. New ant/psychotics: The present status. Int Clin Psychopharmacol 1995, 10 (Suppl.3): 39-48.
34. 3 recognition sites: Fact or artifact? Eur J Pharmacol 1989, 171: 137-9.
35. 2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics. Neurosci Lett 1994, 181: 65-8.
36. 1A receptors. Neuropharmacology 1996, 35: 119-21.
37. Hoffman, D.C., Donovan, H., Gates, M.R., Bankoski, C.A., Cassella, J.V. The effects of atypical and novel antipsychotic drugs on phencyclidine-induced disruption of prepulse inhibition in rats. Abstr Soc Neurosci 1996, 22: 1677.
38. 2A receptors. Eur J Pharmacol 1995, 280: R9-11.
39. Hernandez, L., Auerbach, S., Hoebel, B.G. Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci 1988, 42: 1713-23.
40. Loschner, W., Honack, D. The behavioral effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 1992, 215: 199-208.
41. Krystal, J.H., Karper, L.P., Seibyl, J.P. et al. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51: 199-214.
42. Lahti, A.C., Koffil, B., LaPorte, D., Tamminga, C. A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13: 9-19.
43. Olney, J.E., Farber, N.B. Glutamate receptor dysfunction in schizophrenia. Arch Gen Psychiatry 1995, 52: 998-1007.
44. Tsai, G., Passani, L., Slusher, B. et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995, 52: 829-36.
45. Toru, M., Kurumaji, A., Ishimaru, M. Excitatory amino acids: Implications for psychiatric disorders research. Life Sci 1994, 55: 1683-99.
46. Akbarian, S., Sucher, N.J., Bradley, D. et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996, 16: 19-30.
47. Kerwin, R., Patel, S., Meldrum, B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990, 39: 25-32.
48. Murray, A.M., Weickert, C.S., Shashidharan, P., Hyde, T.M., Kleinman, J.E. Decreased neuronspecific excitatory amino acid transporter 3 in schizophrenic hippocampus. Abstr Soc Neurosci 1996, 22: 1680.
49. Johnson, S.A., Larson, J., Luu, N.T., Lutz, D.L., Rogers, G., Lynch, G. Antagonism of methamphetamine-induced hyperactivity in rats by specific facilitation of AMPA-receptor-mediated glutamatergic transmission. Abstr Soc Neurosci 1996, 22: 1676.
50. Bunney, B.S., Grace, A.A. Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 1978, 23: 1715-28.
51. White, F.J., Wang, R.X. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983, 221: 1054.
52. Chiodo, L.A., Bunney, B.S. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A-9 and A-10 midbrain dopaminergic neurons. J Neurosci 1983, 3: 1607-19.
53. Chiodo, L.A., Bunney, B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 1985, 5: 2538-44.
54. Grace, A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41: 1-24.
55. Bunney, B.S. Effects of acute and chronic neuroleptic treatment on the activity of midbrain dopamine neurons. Ann NY Acad Sci 1988, 537: 77-85.
56. Moghaddam, B., Bunney, B.S. Depolarization inactivation of dopamine: Terminal release characteristics. Synapse 1993, 14: 195-200.
57. Egan, M.F., Chrapusta, S., Karoum, F., Lipska, B.K., Wyatt, R.J. Effects of chronic neuroleptic treatment on dopamine release: Insights from studies using 3-methoxytyramine. J Neural Transm 1996, 103: 777-805.
58. Sagar, S.M., Sharp, F.R., Curran, T. Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science 1988, 240: 1328-31.
59. Morgan, J.I., Curran, T. Stimulus-transcription coupling in neurons: Role of cellular immediate early genes. Trends Neurosci 1989, 12: 459-62.
60. Morgan, J.I., Curran, T. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991, 14: 421-51.
61. Deutch, A.Y., Lee, M.C., Iadarola, M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992, 3: 332-41.
62. 2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 1990, 37: 287-94.
63. Merchant, K.M., Dobner, P.R., Dorsa, D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci 1992, 12: 652-63.
64. 3 receptors mediate clozapine-induced c-fos expression in the forebrain. Abstr Soc Neurosci 1995, 21: 1707.
65. Guo, N., Klitenick, M.A., Tham, T.-S., Fibiger, H.C. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 1995, 65: 747-56.
66. Sebens, J.B., Koch, T., Ter Horst, G.J. Korf, J. Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol 1995, 273: 175-82.
67. Robertson, G.S., Fibiger, H.C. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46: 315-26.
68. Robertson, G.S., Matsumura, H., Fibiger, H.C. Induction of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271: 1058-66.
69. Fink-Jensen, A., Kristensen, P. Effects of typical and atypical neuroleptics on Fos protein expression in rat forebrain. Neurosci Lett 1994, 182: 115-8.
70. 3 receptors. Cereb Cortex 1996, 6: 561-70.
71. Deutch, A.Y., Duman, R.S. The effects of antipsychotic drugs on prefrontal cortical Fos expression: Cellular localization and pharmacological characterization. Neuroscience 1995, 70: 377-89.
72. 4 receptors. In: Pharmacological Regulation of Gene Expression in the CNS. Merchant, K.M. (Ed.). CRC Press: Boca Raton 1996, 25-50.
73. Deutch, A.Y., Ongur, D., Duman, R.S. Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus, a novel locus of antipsychotic drug action. Neuroscience 1995, 66: 337-46.
74. MacGibbon, G.A., Lawlor, P.A., Bravo, R., Dragunow, M. Clozapine and haloperidol produce a differential pattern of immediate gene expression in rat caudate putamen, nucleus accumbens, lateral septum, and Islands of Calleja. Mol Brain Res 1994, 23: 21-32.
75. Nakabeppu, Y., Nathans, D. A naturally occurring truncated form of FosB that inhibts Fos/Jun transcriptional activity. Cell 1991, 64: 751-9.
76. Vahid-Ansari, F., Nakabeppu, Y., Robertson, G.S. Contrasting effects of chronic clozapine, seroquel (ICI 204,636) and haloperidol administration on η FosB-like immunoreactivity in the rat forebrain. Eur J Neurosci 1996, 8: 927-36.
77. Hiroi, N., Graybiel, A.M. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. In press.
78. Merchant, K.M., Dorsa, D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci 1993, 90: 3447-51.
79. Robertson, G.S., Tetzlaff, W., Bedard, A., St-Jean, M., Wigle, N. C-fos mediates antipsychotic-induced neurotensin gene expression in the rodent striatum. Neuroscience 1995, 67: 325-44.
80. 2-like receptor. Abstr Soc Neurosci 1996, 22: 2008.
81. Sams-Dodd, F. Phencyclidine-induced stereotyped behavior and social isolation in the rat: A possible animal model of schizophrenia. Behav Pharmacol 1996, 7: 3-23.
82. Moghaddam, B., Verma, A., Jedema, H., Bagley, J. Neurochemical and behavioral studies of dopamine-glutamate interactions in the prefrontal cortex. Abstr Am Coll Neuropsychopharmacol 1996, 35: 72.
83. 4 receptor antagonist NGD 94-1 ameliorate cognitive impairments in a non-human primate model of schizophrenia. Abstr Am Coll Neuropsychopharmacol 1996, 35: 267.
84. Murphy, B.L., Arnsten, A.F.T., Goldman-Rakic, P.S., Roth, R. H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 1996, 93: 1325-9.
85. Arnsten, A.F.T. Dopamine mechanisms influencing prefrontal cognitive functioning in rats and monkeys. Abstr Am Coll Neuropsychopharmacol 1996, 35: 72.
86. Brown, A.S., Susser, E.S., Butler, P.D., Richardson, A.R., Kaufmann, C.A., Gorman, J.M. Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. J Nerv Ment Dis 1996, 184: 71-85.
87. Plotsky, P.M., Eisler, J.A., Thrivikraman, K.V., Anand, K.J.S., Meaney, M.J. Early experience as a factor in sculpting the developing brain. Abstr Am Coll Neuropsychopharmacol 1996, 35: 12.
88. Jones, G.H., Hernandez, T.D., Kendall, D.A., Marsden, C.A., Robbins, T.W. Dopaminergic and serotonergic function following isolation rearing in rats: Study of behavioral responses and postmortem and in vivo neurochemistry. Pharmacol Biochem Behav 1992, 43: 17-35.
89. Solbrig, M.V., Koob, G.F., Joyce J.N., Lipkin, W.I. A neural substrate of hyperactivity in borna disease: Changes in brain dopamine receptors. Virology 1996, 222: 332-8.
90. Gilmore, J.H., Jarskod, L.F., Watson, N.F., Xiao, H. Neonatal infection increases expression of BDNF and NT-3 mRNA in the hippocampus. Abstr Am Coll Neuropsychopharmacol 1996, 35: 114.
91. Rakic, P. Experimental deletion of specific cortical neurons: Relevance to schizophrenia. Abstr Am Coll Neuropsychopharmacol 1996, 35: 91.
92. Johnston, M.V., Barks, J., Greenmyre, T., Silverstein, F. Use of toxins to disrupt neurotransmitter circuitry in the developing brain. Prog Brain Res 1988, 73: 425-46.
93. Lipska, B.K., Jaskiw, G.E., Weinberger, D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology 1993, 9: 67-75.
94. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 1996, 16: 2020-6.
95. Chambers, R.A., Moore, J., McEvoy, J.P., Levin, E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996, 15: 587-94.
96. Black M.D., Hitchcock, J.M., Sorensen, S.M. Neonatal hippocampal lesion model of schizophrenia in rats: Sex differences and persistence of effects into maturity. Abstr Soc Neurosci 1996, 22: 1676.
97. Stine, C.D., Xue, C.J., Wolf, M.E. Microdialysis studies of excitatory amino acid transmitters in a rat model of schizophrenia. Abstr Soc Neurosci 1996, 22: 1675.
98. Sams-Dodd, F., Lipska, B.K., Weinberger, D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behavior in adulthood. Psychopharmacology, in press.
99. Kolachana, B.S., Saunders, R.C., Bachevalier, J., Weinberger, D.R. Abnormal prefrontal cortical regulation of striatal dopamine release after neonatal medial temporal-limbic lesions in rhesus monkey. Abstr Soc Neurosci 1996, 22: 1974.
100. Beauregard, M., Bachevalier, J. Neonatal insult to the hippocampal region and schizophrenia: A review and a putative animal model. Can J Psychiatry 1996, 41: 446-56.
101. Lipska, B.K., Weinberger, D.R. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Dev Brain Res 1993, 75: 213-22.
102. Lipska, B.K., Weinberger, D.R. Subchronic treatment with haloperidol or clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 1994, 10: 199-205.
103. Lipska, B.K., Weinberger, D.R. Gonadectomy does not prevent novelty-or drug-induced hyperresponsiveness in rats with neonatal excitotoxic hippocampal damage. Dev Brain Res 1994, 78: 253-8.
104. Lipska, B.K., Chrapusta, S.J., Egan, M.F., Weinberger, D.R. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild chronic stress and haloperidol treatment. Synapse 1995, 20: 125-30.
105. Al-Amin, H.A., Lipska, B.K., Weinberger, D.R. Differential effects of haloperidol and clozapine on the MK-801-induced behaviors in rats with neonatal hippocampal lesions. Abstr Am Coll Neuropsychopharmacol 1996, 35: 196.
106. Lipska, B.K., Swerdlow, N.R., Geyer, M.A., Jaskiw, G.E., Braff, D.L., Weinberger, D.R. Neonatal excitotoxic hippocampal damage in rats causes postpubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 1995, 122: 35-43.
107. Lipska, B.K., Moghaddam, B., Sams-Dodd, F., Verma, A., Weinberger, D.R. Neonatal hippocampal damage in the rat models negative symptoms of schizophrenia. Abstr Am Coll Neuropsychopharmacol 1996, 35: 127.
108. Kinon, B.J., Lieberman, J.A. Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology 1996, 124: 2-34.
109. Weinberger, D.R., Lipska, B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: In search of common ground. Schiz Res 1995, 16: 87-110.